What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.79%
Annual Rate
USD 0.35Paid unknown
Payout Ratio
17.8%Sustainable
Paying Dividends
3 yr
Last Ex-Dividend
Jul 7, 2026
Last Payment
Jul 14, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.12BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Trailing P/E
22.43x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue (TTM)
2.10BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Profit Margin
19.49%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Beta
0.6260x
vs all stocks
Updated Sep 28, 2026
52-Week Change
0.55%
vs all stocks
Updated Sep 28, 2026
Forward Annual Dividend Yield
0.79%
vs all stocks
Updated Sep 28, 2026
Market Capitalization
9.12BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Enterprise Value
9.98BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Trailing P/E
22.43x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Forward P/E
16.91x
vs Diagnostics & Research peers
Updated Sep 28, 2026
PEG Ratio
2.82x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Sales (TTM)
4.34x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Book (MRQ)
2.72x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to Revenue
4.75x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to EBITDA
13.60x
vs Diagnostics & Research peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 12.87×.Updated Sep 28, 2026
Gross Margin
63.62%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 66.38%.Updated Sep 28, 2026
Profit Margin
19.49%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Margin
26.32%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Assets (TTM)
5.87%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Equity (TTM)
11.93%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue (TTM)
2.10BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Revenue per Share (TTM)
10.16USDUpdated Sep 28, 2026
Quarterly Revenue Growth
0.30%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Gross Profit (TTM)
1.39BUSD
vs all stocks (USD)
Updated Sep 28, 2026
EBITDA (TTM)
775.41MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Net Income (TTM)
409.32MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Quarterly Earnings Growth (YoY)
7.40%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Cash Flow (TTM)
654.47MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Levered Free Cash Flow (TTM)
372.86MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Forward Annual Dividend Rate
0.3500USDUpdated Sep 28, 2026
Forward Annual Dividend Yield
0.79%
vs all stocks
Updated Sep 28, 2026
Trailing Annual Dividend Rate
0.3630USDUpdated Sep 28, 2026
Trailing Annual Dividend Yield
0.81%
vs all stocks
Updated Sep 28, 2026
Payout Ratio
17.79%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue
2.09BUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
790.50MUSDFY2025 · Dec 31, 2025
Gross Profit
1.30BUSDFY2025 · Dec 31, 2025
Operating Income
520.31MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
490.26MUSDFY2025 · Dec 31, 2025
Income Tax Expense
65.39MUSDFY2025 · Dec 31, 2025
Net Income
424.88MUSDFY2025 · Dec 31, 2025
EBIT
523.52MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
771.73MUSDFY2025 · Dec 31, 2025
Research & Development
187.52MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
583.67MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
64.32MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
33.26MUSDFY2025 · Dec 31, 2025
EPS (Basic)
2.06USDFY2025 · Dec 31, 2025
EPS (Diluted)
2.04USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
206.36MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
206.36MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
424.88MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
670.72MUSDFY2025 · Dec 31, 2025
Free Cash Flow
469.67MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
839.00MUSDFY2025 · Dec 31, 2025
Income Tax Paid
17.27MUSDFY2025 · Dec 31, 2025
Interest Paid
29.25MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
424.88MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
193.75MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-20.07MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
50.40MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
16.47MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-36.39MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
-8.42MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
50.10MUSDFY2025 · Dec 31, 2025
Capital Expenditures
-201.05MUSDFY2025 · Dec 31, 2025
Net Intangibles (CF)
-6.08MUSDFY2025 · Dec 31, 2025
Net Acquisitions
-291.23MUSDFY2025 · Dec 31, 2025
Purchase of Investments
-371.82MUSDFY2025 · Dec 31, 2025
Sale of Investments
597.06MUSDFY2025 · Dec 31, 2025
Other Investing Activity
-32.16MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
-299.20MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
742.32MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-534.17MUSDFY2025 · Dec 31, 2025
Common Dividends Paid
-54.24MUSDFY2025 · Dec 31, 2025
Other Financing Charges
-332.88MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-178.98MUSDFY2025 · Dec 31, 2025
Shares Outstanding
206.50MSharesUpdated Sep 28, 2026
Float Shares
205.13MSharesUpdated Sep 28, 2026
Shares Short
7.66MSharesUpdated Sep 28, 2026
Short Ratio
2.96days
vs all stocks
Updated Sep 28, 2026
Short % of Shares Outstanding
4.20%
vs all stocks
Updated Sep 28, 2026
% Held by Insiders
0.48%
vs all stocks
Updated Sep 28, 2026
% Held by Institutions
79.16%
vs all stocks
Updated Sep 28, 2026
Total Cash (MRQ)
793.50MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Cash per Share (MRQ)
3.84USDUpdated Sep 28, 2026
Total Debt (MRQ)
1.65BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Debt to Equity (MRQ)
0.4925x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Current Ratio (MRQ)
2.85x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Book Value per Share (MRQ)
16.26USDUpdated Sep 28, 2026
Total Assets
6.28BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.00BUSDFY2025 · Dec 31, 2025
Total Liabilities
2.50BUSDFY2025 · Dec 31, 2025
Total Non-current Assets
4.29BUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.99BUSDFY2025 · Dec 31, 2025
Total Current Liabilities
512.14MUSDFY2025 · Dec 31, 2025
Cash
136.54MUSDFY2025 · Dec 31, 2025
Cash Equivalents
702.46MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
839.00MUSDFY2025 · Dec 31, 2025
Other Short-term Investments
259.91MUSDFY2025 · Dec 31, 2025
Accounts Receivable
402.61MUSDFY2025 · Dec 31, 2025
Inventory
301.89MUSDFY2025 · Dec 31, 2025
Accounts Payable
72.66MUSDFY2025 · Dec 31, 2025
Short-term Debt
28.84MUSDFY2025 · Dec 31, 2025
Deferred Revenue
79.42MUSDFY2025 · Dec 31, 2025
Other Current Liabilities
94.25MUSDFY2025 · Dec 31, 2025
Long-term Debt
1.78BUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
207.41MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
2.53MUSDFY2025 · Dec 31, 2025
Retained Earnings
2.75BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
3.78BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
31.82MUSDFY2025 · Dec 31, 2025
52-Week Low
32.53USDUpdated Sep 28, 2026
52-Week High
57.82USDUpdated Sep 28, 2026
52-Week Change
0.55%
vs all stocks
Updated Sep 28, 2026
Beta
0.6260x
vs all stocks
Updated Sep 28, 2026
50-Day MA
42.75USDUpdated Sep 28, 2026
200-Day MA
42.49USDUpdated Sep 28, 2026
Avg 10-Day Volume
1.83MSharesUpdated Sep 28, 2026
Avg 30-Day Volume
2.42MSharesUpdated Sep 28, 2026
Diluted EPS (TTM)
1.97USDUpdated Sep 28, 2026
Other Income / Expense
-61.11MUSDFY2025 · Dec 31, 2025
2 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.